CEO interview in BioStock
January 7, 2020
-
Interim Report 1 2022/23
Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.
-
Wake Forest Institute for Regenerative Medicine Welcomes PHI
PHI visits the WFIRM to finalize an agreement concerning the automation of advanced quality control in large-scale biomanufacturing of regenerative therapies.
-
Year-end Report 2021/22
Sales more than doubled in 2021/22, compared to previous financial year.
